

Key publications

1. Mathew G, Sinha A, Ahmed A, Grewal N, Khandelwal P, Hari P, Bagga A. Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid sensitive nephrotic syndrome: An open label pilot randomized controlled trial. *Pediatric Nephrology* 2022 Mar 14; 1-10.
2. Khandelwal P, Bhardwaj S, Singh G, Sinha A, Hari P, Bagga A. Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. *PediatrNephrol*. 2021;36:591-600
3. Kainth D, Hari P, Sinha A, Pandey S, Bagga A. Short-duration prednisolone in children with nephrotic syndrome relapse: A noninferiority randomized controlled trial. *Clin J Am SocNephrol*. 2021;16:225-232
4. Khandelwal P, Krishnasamy S, Govindarajan S, Kumar M, Marik B, Sinha A, Hari P, Bagga A. Anti-factor H antibody associated hemolytic uremic syndrome following SARS-CoV-2 infection. *PediatrNephrol*. 2022;1-6; doi: 10.1007/s00467-021-05390-4
5. Krishnasamy S, Mantan M, Mishra K, Kapoor K, Brijwal M, Kumar M, Sharma S, Swarnim S, Gaiand R, Khandelwal P, Hari P, Sinha A, Bagga A. SARS-CoV-2 infection in children with chronic kidney disease. *PediatrNephrol* 2021;10.1007/s00467-021-05218-1
6. Joshi A, Sinha A, Sharma A, Shamim U, Uppilli B, Sharma P, Zahra S, Parveen S, Mathur A, Chandan M, Tewari P, Khandelwal P, Hari P, Mukerji M, Faruq M, Bagga A; NephQuest Consortium. Next-generation sequencing for congenital nephrotic syndrome: A multi-center cross-sectional study from India. *Indian Pediatr* 2021; 58:445-451
7. Sinha A, Bagga A, Banerjee S, Mishra K, Mehta A, Agarwal I, Uthup S, Saha A, Mishra OP; For Indian Society of Pediatric Nephrology. Steroid sensitive nephrotic syndrome: Revised guidelines. *Indian Pediatr*. 2021; 58: 461-481.
8. Vasudevan A, Thergaonkar R, Mantan M, Sharma J, Khandelwal P, Hari P, Sinha A, Bagga A; Expert Group of The Indian Society of Pediatric Nephrology. Consensus guidelines on management of steroid-resistant nephrotic syndrome. *Indian Pediatr*. 2021; 58: 650-666
9. Vasudevan A, Mantan M, Krishnamurthy S, Pais P, Mathew G, Hari P, Kanitkar M, Gulati S, Bagga A, Mishra OP; Indian Society of Pediatric Nephrology. Managing children with renal diseases during the COVID-19 pandemic. *Indian Pediatr* 2020;57:641-651
10. Schijvens AM, Sinha A, Bagga A, Schreuder MF. Need for uniform definitions in childhood nephrotic syndrome. *Nephrol Dial Transplant*. 2021; 36: 941-945
11. Bagga A, Sinha A. Individualizing treatment of steroid-resistant nephrotic syndrome: Registries to the fore. *Clin J Am SocNephrol*. 2020;15:920-922
12. Bagga A, Sinha A. Renal tubular acidosis. *Indian J Pediatr*. 2020;87:733-744
13. Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Sinha A, Bagga A, Hogan J, et al. Both the rituximab dose and maintenance immunosuppression in steroid-dependent nephrotic syndrome have important effects on outcomes. *Kidney Int* 2020;97:393-401
14. Khandelwal P, Mahesh V, Mathur VP, Raut S, Geetha TS, Nair S, Hari P, Sinha A, Bagga A. Phenotypic variability in distal acidification defects associated with WDR72 mutations. *PediatrNephrol* 2021; 36: 881-887
15. Carter SA, Gutman T, Logeman C, Cattran D, Lightstone L, Bagga A, et al; SONG-GD Investigators. Identifying outcomes important to patients with glomerular disease and their caregivers. *Clin J Am SocNephrol*. 2020;15:673-684

16. Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, Hui NK, Boyer O, Saleem MA, Feltran L, Müller-Deile J, Becker JU, Cano F, Xu H, Lim YN, Smoyer W, Anochie I, Nakanishi K, Hodson E, Haffner D; International Pediatric Nephrology Association. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. *PediatrNephrol* 2020; 35: 1529-1561
17. Meena J, Bagga A. Current perspectives in management of edema in nephrotic syndrome. *Indian J Pediatr* 2020;87:633-640
18. Meena J, Mathew G, Hari P, Sinha A, Bagga A. Prevalence of bladder and bowel dysfunction in toilet-trained children with urinary tract infection and/or primary vesicoureteral reflux: A systematic review and meta-analysis. *Front Pediatr* 2020; 8: 84.
19. Raut S, Khandelwal P, Sinha A, Thakur R, Puraswani M, Velpandian T, Hari P, Bagga A. Infantile nephropathic cystinosis: Clinical features and outcome. *Asian J PediatrNephrol* 2020;3:15-20
20. Thergaonkar RW, Hari P. Current management of urinary tract infection and vesicoureteral reflux. *Indian J Pediatr*. 2020;87:625-632
21. Meena J, Sinha A. Evaluation for vesicoureteric reflux following febrile urinary tract infections. *Indian J Pediatr* 2019; 86:773-774
22. Kushwah S, Yadav M, Hari P, Meena J, Sinha A, Bagga A. Incidence and determinants of acute kidney injury in patients with nephrotic syndrome. *Asian J PediatrNephrol* 2019; 2: 75-81
23. Sundararaju S, Sinha A, Hari P, Lodha R, Bagga A. Renal angina index in the prediction of acute kidney injury in critically ill children. *Asian J PediatrNephrol* 2019; 2: 25-30
24. Bhasym A, Gurjar BS, Prabhu S, Puraswani M, Khandelwal P, Saini H, Saini S, Chatterjee P, Bal V, George A, Coshic P, Patidar G, Hari P, Sinha A, Bagga A, Rath S, Guchhait P. Altered peripheral blood leukocyte phenotype and responses in healthy individuals with homozygous deletion of FHR1 and FHR3 genes. *J ClinImmunol* 2019; 39: 336-345
25. Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J, Patnaik SK, Sinha A, Sethi S, Hari P, Dragon-Durey MA; Indian Society of Pediatric Nephrology. Hemolytic uremic syndrome in a developing country: Consensus guidelines. *PediatrNephrol*. 2019; 34: 1465-1482
26. Khandelwal P, Thomas CC, Rathi BS, Hari P, Tiwari AN, Sinha A, Bagga A. Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety. *J ClinApher* 2019; 34: 555-562
27. Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS, Sinha A, Shende RP, Maiti TK, Singh AK, Kanga U, Ali U, Agarwal I, Anand K, Prasad N, Rajendran P, Sinha R, Vasudevan A, Saxena A, Agarwal S, Hari P, Sahu A, Rath S, Bagga A. Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: A nationwide database. *Front Immunol* 2019; 10: 1282
28. Bharati J, Bhatia D, Khandelwal P, Gupta N, Sinha A, Khadgawat R, Hari P, Bagga A. C-Terminal fibroblast growth factor-23 levels in non-nutritional hypophosphatemic rickets. *Indian J Pediatr* 2019; 86: 555-557
29. Yadav M, Sinha A, Khandelwal P, Hari P, Bagga A. Efficacy of low-dose daily versus alternate-day prednisolone in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. *PediatrNephrol* 2019; 34:829-835
30. Gruppen MP, Bouts AH, Jansen-van der Weide MC, Merkus MP, Zurowska A, MaternikM, Bagga A, et al; all members of the LevamisoleStudy Group. A randomized clinical trial indicates that

levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome. *Kidney Int.* 2018; 93:510-518

31. Gurjar BS, Manikanta ST, Bhasym A, Prabhu S, Puraswani M, Hari P, Sinha A, Bagga A. Characterization of genetic predisposition and autoantibody profile in atypical haemolytic-uraemic syndrome. *Immunology* 2018; 154: 663-672
32. Khandelwal P, Birla S, Bhatia D, Puraswani M, Saini H, Sinha A, Hari P, Sharma A, Bagga A. Mutations in membrane cofactor protein (CD46) gene in Indian children with hemolytic uremic syndrome. *Clin Kidney J.* 2018; 11: 198-203
33. Yoganathan S, Bagga A, Gulati S, Toteja GS, Hari P, Sinha A, Pandey RM, Irshad M. Prevalence and predictors of peripheral neuropathy in nondiabetic children with chronic kidney disease. *Muscle Nerve.* 2018 May;57(5):792-798. Doi: 10.1002/mus.26027. Epub 2018 Feb 14.
34. Marik B, Bagga A, Sinha A, Hari P, Sharma A. Genetics of Refractory Rickets: Identification of Novel PHEX Mutations in Indian Patients and a Literature Update. *J Pediatr Genet.* 2018;7:47-59
35. Thergaonkar RW, Narang A, Gurjar BS, Tiwari P, Puraswani M, Saini H, Sinha A, Varma B, Mukerji M, Hari P, Bagga A. Targeted exome sequencing in anti-factor H antibody negative HUS reveals multiple variations. *ClinExpNephrol.* 2018; 22: 653-660.
36. Hari P, Khandelwal P, Satpathy A, Hari S, Thergaonkar R, Lakshmy R, Sinha A, Bagga A. Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial. *PediatrNephrol*2018; 33: 2299-2309.
37. Sinha A, Puraswani M, Kalaivani M, Goyal P, Hari P, Bagga A. Efficacy and safety of mycophenolatemofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. *Kidney Int.* 2019; 95: 210-218.
38. Sinha A, Bagga A. Levamisole: Standard or Intensive Therapy? *Indian Pediatr* 2017; 54:815-816
39. Cerdá J, Mohan S, Garcia-Garcia G, Jha V, Samavedam S, Gowrishankar S, BaggaA, Chakravarthi R, Mehta R. Acute kidney injury recognition in low- and middle-income countries. *Kidney Int Rep.* 2017;2:530-543
40. Sinha A, Bagga A. Spectrum of ANCA-associated vasculitis. *Indian J Pediatr.*2017; 84:737-738
41. Kashani K, Macedo E, Burdmann EA, Hooi LS, Khullar D, Bagga A, ChakravarthiR, Mehta R. Acute kidney injury risk assessment: differences and similarities between resource-limited and resource-rich countries. *Kidney Int Rep.* 2017; 2:519-529
42. Mehta R, Bagga A, Patibandlam R, Chakravarthi R. Detection and management of AKI in the developing world: The 18th Acute Disease Quality Initiative (ADQI) International Consensus Conference. *Kidney Int Rep* 2017; 2: 515–518
43. Kher V, Srisawat N, Noiri E, Gharbi MB, Shetty MS, Yang L, Bagga A, et al. Prevention and therapy of acute kidney injury in the developing world. *Kidney Int Rep* 2017; 2: 544–558
44. Annigeri RA, Ostermann M, Tolwani A, Vazquez-Rangel A, Ponce D, Bagga A, et al. Renal support for acute kidney injury in the developing world. *Kidney Int Rep* 2017; 2: 559–578
45. Silver SA, Adu D, Agarwal S, Gupta KL, Lewington AJP, Pannu N, Arvind Bagga A, et al. Strategies to enhance rehabilitation after acute kidney injury in the developing world. *Kidney Int Rep* 2017; 2: 579–593
46. Gipson DG, Selewski DT, Massengill SF, Modes MM, Desmond H, Lee L, Sinha A, Bagga A, et al. NephCure Accelerating Cures Institute: A multidisciplinary consortium to improve care for nephrotic syndrome. *Kidney Int Rep* 2017; 3: 439–446

47. Sinha A, Gupta A, Kalaivani M, Hari P, Dinda AK, Bagga A. Mycophenolatemofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome. *Kidney Int.* 2017;92:248-257
48. Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Bagga A, et al; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. *Kidney Int.* 2017; 91:539-551.